NCT07242612 Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
| NCT ID | NCT07242612 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Khyber Medical University Peshawar |
| Condition | Osteoporosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-03-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-10-01 with a primary completion date of 2026-03-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates the use of blood tests known as Bone Turnover Markers (BTMs) to quickly monitor the effectiveness of osteoporosis treatment in postmenopausal women. Osteoporosis, which weakens bones and increases fracture risk, is typically monitored using a DEXA scan to measure bone density (BMD), but this method changes slowly. BTMs may show a response to medication within just 3 to 6 months. In this randomized controlled trial, 40 postmenopausal women with osteoporosis will be assigned to receive either antiresorptive drugs (which slow bone loss) or anabolic drugs (which build new bone), along with calcium and vitamin D. The study will compare how these treatments affect BTMs and BMD over six months to determine if BTMs can serve as an early and reliable indicator of treatment success, which could be particularly useful in regions like Pakistan where access to repeated DEXA scans is limited.
Eligibility Criteria
Inclusion Criteria: * Postmenopausal women (at least one year since last menstrual cycle). * Age greater than 50 years. * Diagnosis of primary osteoporosis. * Currently not on any anti-osteoporosis medications. * Not taking Calcium or Vitamin D supplements. * Volunteer to participate and provide informed consent. Exclusion Criteria: * Women with multiple vertebral fractures or severe lumbar degenerative changes. * Use of hormone/estrogen therapy, calcitonin, oral bisphosphonates, IV ibandronate, IV Zoledronic acid, denosumab, or teriparatide within the past 18 months. * Use of corticosteroids (short or long-term). * History of hyperthyroidism, hypothyroidism, liver disease, kidney disease, or tumors. * Presence of secondary causes of osteoporosis (e.g., eating disorders, celiac disease, diabetes, hematologic disorders).
Contact & Investigator
Asma Mehmood, PhD Scholar
PRINCIPAL INVESTIGATOR
Institute of Basic Medical Sciences, Khyber Medical University
Frequently Asked Questions
Who can join the NCT07242612 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Osteoporosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07242612 currently recruiting?
Yes, NCT07242612 is actively recruiting participants. Contact the research team at asma13mehmood@gmail.com for enrollment information.
Where is the NCT07242612 trial being conducted?
This trial is being conducted at Peshawar, Pakistan.
Who is sponsoring the NCT07242612 clinical trial?
NCT07242612 is sponsored by Khyber Medical University Peshawar. The principal investigator is Asma Mehmood, PhD Scholar at Institute of Basic Medical Sciences, Khyber Medical University. The trial plans to enroll 40 participants.